HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection

Stock News

06/10

HANSOH PHARMA (03692) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.

The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.

HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1141642657"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141642657\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141642657?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141642657","market":"hk","top_or_hot":-1,"title":"HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection","media":"Stock News","content":"<p><b>HANSOH PHARMA</b> (<b>03692</b>) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.<br><br>The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.<br><br>HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-06-10 18:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>HANSOH PHARMA</b> (<b>03692</b>) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.<br><br>The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.<br><br>HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1141642657","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141642657","pubTimestamp":1781088290,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HANSOH PHARMA (03692) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","03692":"翰森制药","BK1583":"高瓴概念","BK1589":"北水核心资产","BK1191":"制药"},"translate_title":"翰森制药HS-10568注射液新药申请获NMPA受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"03692":1},"content_text":"HANSOH PHARMA (03692) has announced that the New Drug Application for its innovative product, HS-10568 injection, has been accepted for review by China's National Medical Products Administration.The application, submitted on June 9, 2026, seeks marketing authorization for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are undergoing hemodialysis.HS-10568, also known under the partner code SHR6508, functions as a calcium-sensing receptor allosteric modulator. Its mechanism of action involves increasing the receptor's sensitivity to extracellular calcium, which subsequently leads to a reduction in the secretion of parathyroid hormone.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}